Prokarium is a biopharmaceutical company focused on developing vaccination and cancer immunotherapy solutions based on synthetic biology. Our oral vaccine delivery platform Vaxonella stimulates broad protective immune responses applicable to a wide range of diseases.

Prokarium’s vision is that all protein vaccines can be delivered orally. Our Vaxonella® platform enables this, while also being a strong stimulator of all arms of immunity, as well as reducing costs and time for vaccine manufacture. Prokarium is based in Keele and London, UK.

Our experience as a team stretches from microbial genetics and immunology to mergers and acquisitions in pharma, business development and accounting. For more detailed information about us as individuals, please follow the links in the below bar.